Distinct sleep and rest-activity profiles according to adjuvant treatment exposure in women treated for breast cancer
Abstract
BACKGROUND: The associations between adjuvant treatment combinations and sleep-wake processes in women treated for breast cancer remain poorly understood, thereby limiting the development of individualized supportive care. This exploratory study aims to investigate this effect in women treated for breast cancer receiving chemotherapy (CT) combined or not with radio- (RT) and endocrine (ET) therapies on sleep-wake processes and cancer-related fatigue. PATIENTS AND METHODS: Sixty participants were evaluated (21 patients receiving CT+RT+ET [CT group], 23 patients receiving RT+ET only [non-CT group], and 16 healthy control women [HC group]). Participants completed questionnaires assessing cancer-related fatigue and sleep complaints and wore a wrist actigraph for 72 hours to extract sleep-derived and rest-activity rhythm (RAR) parameters. General linear model served to compare groups when controlling for age and cancer stage. Correlation matrices were computed using Spearman's correlations to evaluate the links between variables in each patient' group. RESULTS: Sleep complaints and cancer-related fatigue did not significantly differ between groups. The CT group had fewer but longer nocturnal awakenings and shorter sleep-onset latency compared to both non-CT and HC groups. The non-CT group had lower dichotomy index-reflecting robustness of the RAR-than the CT group but did not differ significantly from the HCs. Fatigue was negatively correlated with RAR amplitude in the non-CT group. CONCLUSION: This exploratory study suggests that distinct patterns of sleep-wake parameters may be observed across the treatment exposure- groups (ie, RT and ET + or-CT). These results should not be interpreted as evidence that treatment exposure itself explains the observed sleep-wake differences and require further investigation to be confirmed. CLINICAL TRIAL REGISTRATION NUMBER: NCT04391543 (https://clinicaltrials.gov/study/NCT04391543).
Related
- Distinct inflammatory marker profiles of adolescents and young adults among the HIV risk, infection, and treatment spectrum.
- A candidate gonococcal outer membrane vesicle vaccine which induces persistent immunity in three genetically distinct species of mouse and is similarly immunogenic when formulated with and without aluminium adjuvant
- Evaluation of the Adjuvant Activity of Herniaria glabra Saponin-Based Nanoadjuvants
- Ground beetles in agroforestry system show functional traits and activity-density differences according to distance to trees
- Integrating stool chemistry measurements with metagenomics in adults reveals distinct gut health profiles
BibTeX
@article{leclercq2026distinct,
title = {{Distinct sleep and rest-activity profiles according to adjuvant treatment exposure in women treated for breast cancer}},
author = {Alicia Leclercq and Abderrahmane Rahmani and Baptiste Morel and Antoine Chatrenet and Hugues Bourgeois and Oana Cojocarasu and Clara Mathie and Caroline Fonsegrive and François Gernier and Marie Fernette and Jean-Michel Grellard and Florence Joly and Mylène Duivon and Benedicte Giffard and Joy Perrier and Tristan Martin},
journal = {The Oncologist},
year = {2026},
month = oct,
doi = {10.1093/oncolo/oyag378},
url = {https://hal.science/hal-05777507v1},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Distinct sleep and rest-activity profiles according to adjuvant treatment exposure in women treated for breast cancer
AU - Alicia Leclercq
AU - Abderrahmane Rahmani
AU - Baptiste Morel
AU - Antoine Chatrenet
AU - Hugues Bourgeois
AU - Oana Cojocarasu
AU - Clara Mathie
AU - Caroline Fonsegrive
AU - François Gernier
AU - Marie Fernette
AU - Jean-Michel Grellard
AU - Florence Joly
AU - Mylène Duivon
AU - Benedicte Giffard
AU - Joy Perrier
AU - Tristan Martin
PY - 2026
DA - 2026/10/03
JO - The Oncologist
DO - 10.1093/oncolo/oyag378
UR - https://hal.science/hal-05777507v1
AB - BACKGROUND: The associations between adjuvant treatment combinations and sleep-wake processes in women treated for breast cancer remain poorly understood, thereby limiting the development of individualized supportive care. This exploratory study aims to investigate this effect in women treated for breast cancer receiving chemotherapy (CT) combined or not with radio- (RT) and endocrine (ET) therapies on sleep-wake processes and cancer-related fatigue. PATIENTS AND METHODS: Sixty participants were evaluated (21 patients receiving CT+RT+ET [CT group], 23 patients receiving RT+ET only [non-CT group], and 16 healthy control women [HC group]). Participants completed questionnaires assessing cancer-related fatigue and sleep complaints and wore a wrist actigraph for 72 hours to extract sleep-derived and rest-activity rhythm (RAR) parameters. General linear model served to compare groups when controlling for age and cancer stage. Correlation matrices were computed using Spearman's correlations to evaluate the links between variables in each patient' group. RESULTS: Sleep complaints and cancer-related fatigue did not significantly differ between groups. The CT group had fewer but longer nocturnal awakenings and shorter sleep-onset latency compared to both non-CT and HC groups. The non-CT group had lower dichotomy index-reflecting robustness of the RAR-than the CT group but did not differ significantly from the HCs. Fatigue was negatively correlated with RAR amplitude in the non-CT group. CONCLUSION: This exploratory study suggests that distinct patterns of sleep-wake parameters may be observed across the treatment exposure- groups (ie, RT and ET + or-CT). These results should not be interpreted as evidence that treatment exposure itself explains the observed sleep-wake differences and require further investigation to be confirmed. CLINICAL TRIAL REGISTRATION NUMBER: NCT04391543 (https://clinicaltrials.gov/study/NCT04391543).
SN - 1083-7159
SN - 1549-490X
ER -